Compare ACV & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | BIOA |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 255.6M |
| IPO Year | N/A | 2024 |
| Metric | ACV | BIOA |
|---|---|---|
| Price | $21.03 | $4.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.44 |
| AVG Volume (30 Days) | 28.8K | ★ 640.4K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $114.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.41 | $4.46 |
| 52 Week High | $29.04 | $25.96 |
| Indicator | ACV | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 24.10 | 26.73 |
| Support Level | N/A | N/A |
| Resistance Level | $28.27 | $6.30 |
| Average True Range (ATR) | 0.57 | 0.45 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 0.64 | 0.49 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.